When it comes to cancer, nothing beats primary prevention.

There is a big gap in the prevention weaponry to fight cancer.

DNA Adductomics is a story that has begun, but currently it is fragmented and far from complete… so the biological, clinical and societal impact has been limited.

Filling this big gap, and finishing the story is a significant health and commercial opportunity.

Measuring DNA Adducts for primary cancer prevention is not easy, but the Survalence CaSe Test promises success.